Ligand Pharmaceuticals | LGND - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Agenus USD 38.52M 3.2M 2026-03
Amgen USD 541M 1000K 2026-06
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 141.14M 564K 2026-06
Baxter International USD 517M 549K 2026-06
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Eli Lilly USD 943.5M 3.33M 2026-03
Enanta Pharmaceuticals USD 212K 1000 2023-12
Enviri Corporation USD 81.45M 797K 2025-12
Gilead Sciences USD 1.24B 1000K 2026-06
GlaxoSmithKline GBP 4.08B 20.6M 2026-06
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
Karyopharm Therapeutics USD 22.54M 4.23M 2026-03
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.56M 241K 2026-03
Merck USD 2.47B 4.93M 2026-03
Pacira USD 39.82M 512K 2026-06
Pfizer USD 5.7B 0 2026-06
Rigel Pharmaceuticals USD 17K 158K 2024-06
Veracyte USD 79.79M 1000 2026-06